Omeros’ (OMER) Buy Rating Reiterated at D. Boral Capital

D. Boral Capital reiterated their buy rating on shares of Omeros (NASDAQ:OMER) in a report published on Friday morning,Benzinga reports. They currently have a $36.00 price objective on the biopharmaceutical company’s stock.

A number of other research analysts have also recently weighed in on the stock. Needham & Company LLC restated a “hold” rating on shares of Omeros in a report on Friday, January 17th. StockNews.com cut shares of Omeros from a “hold” rating to a “sell” rating in a report on Friday. One investment analyst has rated the stock with a sell rating, two have assigned a hold rating, two have assigned a buy rating and one has given a strong buy rating to the company’s stock. According to MarketBeat.com, the company presently has a consensus rating of “Moderate Buy” and a consensus target price of $22.50.

Omeros Stock Performance

Omeros stock opened at $9.10 on Friday. The company’s 50 day simple moving average is $8.70 and its 200-day simple moving average is $7.37. The company has a market capitalization of $527.35 million, a price-to-earnings ratio of -3.94 and a beta of 2.03. Omeros has a 1 year low of $2.61 and a 1 year high of $13.60.

Institutional Inflows and Outflows

A number of institutional investors have recently made changes to their positions in the business. Geode Capital Management LLC grew its holdings in Omeros by 0.5% during the 3rd quarter. Geode Capital Management LLC now owns 1,339,251 shares of the biopharmaceutical company’s stock worth $5,318,000 after acquiring an additional 6,839 shares in the last quarter. State Street Corp grew its holdings in Omeros by 0.3% during the 3rd quarter. State Street Corp now owns 1,226,053 shares of the biopharmaceutical company’s stock worth $4,867,000 after acquiring an additional 3,839 shares in the last quarter. Nomura Holdings Inc. grew its holdings in Omeros by 136.2% during the 4th quarter. Nomura Holdings Inc. now owns 747,281 shares of the biopharmaceutical company’s stock worth $7,383,000 after acquiring an additional 430,932 shares in the last quarter. Charles Schwab Investment Management Inc. grew its holdings in Omeros by 4.0% during the 3rd quarter. Charles Schwab Investment Management Inc. now owns 485,035 shares of the biopharmaceutical company’s stock worth $1,926,000 after acquiring an additional 18,454 shares in the last quarter. Finally, Two Sigma Investments LP grew its holdings in Omeros by 8.8% during the 4th quarter. Two Sigma Investments LP now owns 162,991 shares of the biopharmaceutical company’s stock worth $1,610,000 after acquiring an additional 13,201 shares in the last quarter. Institutional investors and hedge funds own 48.79% of the company’s stock.

About Omeros

Omeros Corporation, a clinical-stage biopharmaceutical company, discovers, develops, and commercializes small-molecule and protein therapeutics, and orphan indications targeting immunologic diseases, including complement-mediated diseases, cancers, and addictive and compulsive disorders. The company’s products under development include Narsoplimab (OMS721/MASP-2) that has completed pivotal trial for hematopoietic stem-cell transplant-associated thrombotic microangiopathy (TA-TMA); that is in Phase III clinical trial for the treatment of immunoglobulin A nephropathy (IgAN); and Phase II clinical trial to treat COVID-19.